Insiders Updates Investing in Protalix BioTherapeutics Inc. (PLX): What You Must Know Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct
Stock Earnings H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct
Featured Protalix BioTherapeutics Inc. (PLX) stock is falling in premarket, Why is this happening? Protalix BioTherapeutics, Inc. (NYSE American: PLX) a biopharmaceutical company focused on manufacturing recombinant therapeutic proteins with clinically improved profiles, confirmed receiving